DE69627365T2 - Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten - Google Patents

Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten Download PDF

Info

Publication number
DE69627365T2
DE69627365T2 DE69627365T DE69627365T DE69627365T2 DE 69627365 T2 DE69627365 T2 DE 69627365T2 DE 69627365 T DE69627365 T DE 69627365T DE 69627365 T DE69627365 T DE 69627365T DE 69627365 T2 DE69627365 T2 DE 69627365T2
Authority
DE
Germany
Prior art keywords
drug
hyaluronic acid
solution
pain
polymer matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69627365T
Other languages
German (de)
English (en)
Other versions
DE69627365D1 (de
Inventor
Alan Downsview DRIZEN
Peter Toronto ROTHBART
Gary M. Bethesda NATH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAM Pharmaceutical Corp USA
Original Assignee
LAM Pharmaceutical Corp USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27415224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69627365(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/630,205 external-priority patent/US5716631A/en
Application filed by LAM Pharmaceutical Corp USA filed Critical LAM Pharmaceutical Corp USA
Application granted granted Critical
Publication of DE69627365D1 publication Critical patent/DE69627365D1/de
Publication of DE69627365T2 publication Critical patent/DE69627365T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69627365T 1995-09-29 1996-09-25 Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten Expired - Fee Related DE69627365T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US53675095A 1995-09-29 1995-09-29
US536750 1995-09-29
US58827296A 1996-01-18 1996-01-18
US588272 1996-01-18
US630205 1996-04-10
US08/630,205 US5716631A (en) 1995-09-29 1996-04-10 Long acting narcotic analgesics and antagonists
PCT/US1996/015293 WO1997011681A1 (en) 1995-09-29 1996-09-25 Sustained release delivery system and long acting narcotic analgesics and antagonists

Publications (2)

Publication Number Publication Date
DE69627365D1 DE69627365D1 (de) 2003-05-15
DE69627365T2 true DE69627365T2 (de) 2004-02-12

Family

ID=27415224

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69627365T Expired - Fee Related DE69627365T2 (de) 1995-09-29 1996-09-25 Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten

Country Status (7)

Country Link
EP (1) EP0859597B1 (enExample)
AT (1) ATE236616T1 (enExample)
AU (1) AU7244696A (enExample)
CA (1) CA2233280A1 (enExample)
DE (1) DE69627365T2 (enExample)
ES (1) ES2196180T3 (enExample)
WO (1) WO1997011681A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
US5897880A (en) * 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
US20020177626A1 (en) 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
DE10153673B4 (de) 2001-06-18 2005-04-07 Native Instruments Software Synthesis Gmbh Automatische Erzeugung von musikalischen Scratch-Effekten
DE10358749A1 (de) * 2003-12-12 2005-07-14 Lts Lohmann Therapie-Systeme Ag Darreichungsform zur Bekämpfung von primären Kopfschmerzen
US9155734B2 (en) 2012-03-07 2015-10-13 Mallinckrodt Llc Stability of hydromorphone hydrochloride solutions
JP6074442B2 (ja) * 2012-03-07 2017-02-01 マリンクロッド エルエルシー 塩酸ヒドロモルホン液剤の改良された安定性
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
IT201800001890A1 (it) * 2018-01-25 2019-07-25 Fidia Farm Spa Composizioni farmaceutiche per il trattamento del dolore postoperatorio

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2542616B1 (fr) * 1983-03-17 1987-07-31 Unilever Nv Composition pour le traitement des muqueuses a base d'un antibiotique et d'un hydrocolloide formateur de gel
SE8900586L (sv) * 1989-02-21 1990-08-22 Pharmacia Ab Komposition och foerfarande foer att foerhindra adhesion mellan kroppsvaevnader
US5143724A (en) * 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
EP0516026A1 (en) * 1991-05-28 1992-12-02 Takeda Chemical Industries, Ltd. Hydrogel and method of producing same
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair

Also Published As

Publication number Publication date
EP0859597A1 (en) 1998-08-26
ES2196180T3 (es) 2003-12-16
EP0859597B1 (en) 2003-04-09
EP0859597A4 (enExample) 1998-10-07
WO1997011681A1 (en) 1997-04-03
CA2233280A1 (en) 1997-04-03
ATE236616T1 (de) 2003-04-15
DE69627365D1 (de) 2003-05-15
AU7244696A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
US6063405A (en) Sustained release delivery system
DE69929041T2 (de) Verwendung von cabergolin zur behandlung von "restless legs syndrom"
DE69523295T2 (de) Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung
DE69514794T2 (de) Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
DE60126265T2 (de) Zusammensetzung bestehend aus Phentolaminmesylat und deren Verwendung
DE69932823T2 (de) Apomorphin enthaltende darreichungsformen zur verbesserung der männlichen erektilen dysfunktion
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69017596T2 (de) Verwendung eines Opiatantagonisten zur Herstellung eines transdermal zu verabreichenden Arzneimittels sowie eine Vorrichtung zur transdermalen Verabreichung.
DE60009477T2 (de) Injizierbare naltrexon mikrosphären zusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
DE60133203T3 (de) Fentanyl Zusammensetzung für nasale Anwendung
DE69636413T2 (de) Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe
DE69630947T2 (de) Mittel zur schmerzbehandlung
US6479074B2 (en) Methods and transdermal compositions for pain relief
JP2002519310A (ja) 疼痛軽減のための方法および経皮組成物
DE69627365T2 (de) Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten
US5716631A (en) Long acting narcotic analgesics and antagonists
AT389998B (de) Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung
JPH0780761B2 (ja) 痛みのある疾患又はアレルギー性疾患の治療用組成物及び治療法
WO1997011681A9 (en) Sustained release delivery system and long acting narcotic analgesics and antagonists
BRPI1007812B1 (pt) Lipoatrofia cosmetic medicinal
WO2015024420A1 (zh) 局麻药止痛延时剂
DE69529819T2 (de) Neue kombination eines betablockers mit einem lokalanästhetikum
DE202006018609U1 (de) Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
EP2367546B1 (de) Kombination aus lokalanästhetikum und analgetikum zur linderung von brustschmerz
WO2008113421A1 (de) Neue pharmazeutische zusammensetzungen für die lipolyse und verfahren zu deren herstellung

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee